AbbVie's response to COVID-19

As COVID-19 continues to have an increased impact on our communities, AbbVie is focused on the health and safety of employees, health care professionals and patients and communities worldwide.

"During this challenging time, we are doing everything possible to ensure our employees remain safe, our patients receive their medicines, and assistance is available to help those most deeply impacted by the COVID-19 pandemic."  - Richard Gonzalez, CEO

Supporting COVID-19 clinical research

As a global biopharmaceutical company, AbbVie is involved in a number of efforts to help positively impact the COVID-19 crisis. For example, we have initiated a Phase 2 study of IMBRUVICA in patients with COVID-19 infection. The goal of this study is to determine whether IMBRUVICA is able to improve patient outcomes by diminishing the immune response known as the cytokine storm that contributes to the morbidity and mortality in COVID-19.

You can also learn more about our collaboration with researchers to develop an antibody therapy to prevent and treat COVID-19.

Corporate giving

AbbVie has donated $35 million to help support underserved communities and healthcare systems working to address the impact of the COVID-19 global pandemic. AbbVie’s partners are:

  • International Medical Corps to help create capacity to treat patients at overburdened hospitals in the U.S. AbbVie’s donation will support the creation and operation of 20 mobile field hospitals to expand available triage at existing facilities, improve patient flow and keep COVID-19 patients separated from other patients. These standalone mobile field hospitals are being built in U.S. hotspots.
  • Direct Relief to provide equipment and supplies in the hardest-hit European countries. This support will enable the procurement and delivery of oxygen concentrators, ventilators and personal protective equipment to frontline healthcare workers and patients.
  • Feeding America to protect the most vulnerable, including the elderly, by enabling access to food and essential household supplies with minimal contact. Feeding America has created a new model of home delivery and drive-through service.

Read the full announcement and access the press kit

As part of the company’s $35 million philanthropic commitment to fighting COVID, AbbVie set up a $5 million COVID-19 Community Resilience Fund. In May, the company announced the 26 nonprofits that received funds to help front-line healthcare workers and vulnerable populations in hard-hit communities. Learn more.

AbbVie also doubled the AbbVie Foundation match for COVID-19-related contributions by employees, providing $2 for every $1 employees donate to a qualified nonprofit.

CNBC Special Report - AbbVie donates $35 million to COVID-19 relief efforts

Watch CNBC's Special Report on AbbVie's $35 million donation for COVID-19 relief efforts.

Watch on

Additional resources

We understand your need to know more about the coronavirus. If you are on an AbbVie treatment, please speak with your doctor regarding any questions you may have. Your doctor can provide medical advice to address your individual needs.

Medication assistance

For patients who have lost insurance coverage related to COVID-19, we are here to help.

Through myAbbVie Assist, qualifying patients in the U.S. can receive free AbbVie medicine. If you are unable to pay for your AbbVie medicine due to COVID-19 circumstances, let us help you explore your options. Learn more about myAbbVie Assist.

If you are a registered healthcare provider with questions about COVID-19 and AbbVie medications or adverse event reporting, please visit AbbVie’s medical information website,

Protecting our employees

AbbVie is focused on ensuring the safety of our employees while we continue to make the vital medicines our patients depend on.

AbbVie has taken the following steps to protect the health of our employees:

  • The safety and well-being of employees are AbbVie's most important objectives as we begin to bring employees back to our worksites in a phased approach.
  • We have implemented widespread changes to assure employee safety as people return to the workplace. The company has put strong measures in place to limit exposure risk and keep our worksites as safe as possible, including intense cleaning, temperature testing and requiring social distancing and masks. 
  • Many of our employees who have jobs that can be done remotely continue to work from home.
  • We have enacted strict travel restrictions in accordance with government guidance.

We continue to closely monitor this evolving situation during this unprecedented global health crisis. 


Employees impacted by the coronavirus

If you are an employee that is being impacted by the COVID-19 pandemic and need assistance, the AbbVie Employee Assistance Fund (AEAF) may be able to help. 
Click here to apply and for more information.


Enabling AbbVie healthcare workers as volunteers

AbbVie is committed to supporting the relief efforts of the COVID-19 pandemic crisis. As a global healthcare company, some of our employees may have the experience needed to support government and community organizations during this crisis. The company provides a professional service policy for AbbVie employees with relevant medical, pharmaceutical, research and development, science, public health and public safety skills, knowledge, training and experience who desire, are requested, or mandated to serve as volunteers during times of pandemic crisis. AbbVie colleagues will continue to receive their full pay, benefits, and be able to return to their position after completing their service.

AbbVie is constantly monitoring and taking precautions to protect the safety of our study participants, clinical trial site staff and our employees. We will continue to evaluate any local support our study participants may require to maintain their safe involvement in our clinical trials.

AbbVie Medical Information for healthcare providers

Centers for Disease Control Coronavirus disease 2019 (COVID-19)
CDC website

World Health Organization Coronavirus disease (COVID-19) webpage
WHO website

AbbVie Media Relations
Contact us